Table 1.
Baseline demographics
| Variable | Participants (n=272) |
|---|---|
| Age (years), mean ± SD | 53.7 ± 13.4 |
| Range | 20–79 |
| Male | 156 (57.4%) |
| Race | |
| White | 222 (88.2%) |
| Black | 26 (9.6%) |
| Asian | 9 (3.3%) |
| American Indian | 5 (1.8%) |
| Other/chose not to disclose | 10 (3.7%) |
| Hispanic ethnicity | 25 (9.2%) |
| Pre-transplant dialysis modality | |
| None | 105 (38.6%) |
| Hemodialysis | 119 (43.8%) |
| Peritoneal dialysis | 48 (17.6%) |
| Time on dialysis (years), median [IQR] | 2.9 [0.1–20.1] |
| Calculated panel reactive antibody (cPRA), mean ± SD | 18.6 ± 33.2 |
| Body mass index (kg/m2), mean ± SD | 28.7 ± 5.2 |
| Myocardial infarction | 19 (7.0%) |
| Congestive heart failure | 54 (19.9%) |
| Peripheral vascular disease | 109 (40.1%) |
| Cerebrovascular disease | 36 (13.2%) |
| Chronic obstructive pulmonary disease | 44 (16.2%) |
| Diabetes mellitus | 79 (29.0%) |
| Deceased donor kidney transplant | 90 (33.1%) |
| Induction immunosuppression | |
| Anti-thymocyte globulin | 95 (34.9%) |
| Alemtuzumab | 84 (30.9%) |
| Basiliximab | 93 (34.2%) |
| Maintenance immunosuppression | |
| Tacrolimus/mycophenolate/prednisone | 170 (62.5%) |
| Tacrolimus/mycophenolate | 96 (35.3%) |
| Belatacept/mycophenolate/prednisone | 6 (2.2%) |
| Steroid maintenance therapy | 176 (64.7%) |
SD = standard deviation; IQR = interquartile range;
cPRA = calculate panel reactive antibody